Table 2.
Health Care Claims of Individuals with JIA during transfer
| Pediatric Interval | Transfer Interval | Adult Interval | p value | |
|---|---|---|---|---|
| MTX PO | 10 (17.24 %) | 9 (15.52 %) | 11 (18.97 %) | 0.8 |
| MTX SQ | 4 (6.90 %) | 3 (5.17 %) | 1 (1.72 %) | 0.1 |
| TNFi | 19 (32.76 %) | 14 (24.14 %) | 24 (41.38 %) | 0.2 |
| GC | 16 (27.59 %) | 18 (31.03 %) | 16 (27.59 %) | 1 |
| OP | 16 (27.59 %) | 12 (20.69 %) | 17 (29.31 %) | 0.8 |
| NSAID | 25 (43.10 %) | 21 (36.21 %) | 17 (29.31 %) | 0.06 |
| ER | 11 (18.97 %) | 11 (18.97 %) | 12 (20.69 %) | 0.8 |
| PT | 14 (24.14 %) | 10 (17.24 %) | 11 (18.97 %) | 0.4 |
| Physician diagnosis codes | ||||
| JRA (714.3x) | 41 (70.69 %) | 16 (27.59 %) | <0.0001 | |
| Psoriatic arthritis (696.0) | 3 (5.17 %) | 3 (5.17 %) | 1 | |
| Spondyloarthritis (720.xx) | 16 (27.59 %) | 14 (24.14 %) | 0.3 | |
| RA (714.0) | 0 (0 %) | 26 (44.83 %) | ||
Number of individuals who received medications, had ≥ PT visit, ≥ 1 ER visit, and physician diagnosis codes (not mutually exclusive) during each interval, n (%). The pediatric interval and adult interval proportions were compared by McNemar’s test with resulting p value
Abbreviations: MTX methotrexate, PO oral, SQ subcutaneous, TNFi tumor necrosis factor inhibitor, GC glucocorticoids, OP opiates, ER Emergency Room, PT physical therapy, JRA Juvenile Rheumatoid Arthritis, RA rheumatoid arthritis